Skip to main content
Skip to section navigation
Skip to footer
Home
About
Overview
Management Team
Board of Directors
Advisory Board
Pipeline
Overview
XRx-026 for Gout
XRx-008 for Autosomal Dominant Polycystic Kidney Disease
XRx-101 for Coronavirus/COVID-19
225 for Type 2 Diabetic Nephropathy
Publications
Technology
News & Media
Press Releases
Events
In the News
Investors
Overview
News & Events
Presentations
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR+
Governance
Contact
Press Releases
News & Media
News & Media
Press Releases
Events
In the News
Year
All Years
2025
2024
2023
2022
2021
2020
2019
2018
Sep 10, 2018 7:00am EDT
XORTX Announces Submission of Orphan Drug Designation Application
Aug 13, 2018 7:00am EDT
XORTX Submits FDA pre-IND Meeting Documents
Jun 28, 2018 8:59am EDT
XORTX Reports on Annual Special Meeting and Provides Corporate Update
Jun 08, 2018 7:00am EDT
XORTX Announces Filing of FDA pre-IND Meeting Request Letter
Jun 06, 2018 5:38pm EDT
XORTX to Commence Trading on the OTCQB Venture Market
May 08, 2018 7:00am EDT
XORTX Appoints Chairman
Apr 19, 2018 7:00am EDT
XORTX Announces PKD Foundation Collaboration
Mar 20, 2018 9:24pm EDT
XORTX Announces Issuance of Stock Options
Feb 27, 2018 7:30am EST
XORTX Therapeutics Provides Corporate Update
Feb 22, 2018 7:30am EST
XORTX Therapeutics Appoints Dave Matthews CFO
arrow_back
1…
9
10
11
12
13
14
15
16
17
18
arrow_forward
rss_feed
News RSS